Kılınç, Oğuz
Loading...
Profile URL
Name Variants
Kılınç, Oguz
Kılınc, Oğuz
Kılınç, Oğuz
Kilinc, O.
Kilinç, O.
Kilinc, Oguz
Kilinç, Oguz
Kilinç, Oğuz
Kılınç, O.
Kılınc, Oguz
Kılınc, Oğuz
Kılınç, Oğuz
Kilinc, O.
Kilinç, O.
Kilinc, Oguz
Kilinç, Oguz
Kilinç, Oğuz
Kılınç, O.
Kılınc, Oguz
Job Title
Email Address
oguz.kilinc@ieu.edu.tr
Main Affiliation
09.03. Medicine
Status
Current Staff
Website
ORCID ID
Scopus Author ID
Turkish CoHE Profile ID
Google Scholar ID
WoS Researcher ID
Sustainable Development Goals
1NO POVERTY
1
Research Products
2ZERO HUNGER
0
Research Products
3GOOD HEALTH AND WELL-BEING
4
Research Products
4QUALITY EDUCATION
0
Research Products
5GENDER EQUALITY
0
Research Products
6CLEAN WATER AND SANITATION
0
Research Products
7AFFORDABLE AND CLEAN ENERGY
0
Research Products
8DECENT WORK AND ECONOMIC GROWTH
0
Research Products
9INDUSTRY, INNOVATION AND INFRASTRUCTURE
0
Research Products
10REDUCED INEQUALITIES
0
Research Products
11SUSTAINABLE CITIES AND COMMUNITIES
1
Research Products
12RESPONSIBLE CONSUMPTION AND PRODUCTION
0
Research Products
13CLIMATE ACTION
0
Research Products
14LIFE BELOW WATER
0
Research Products
15LIFE ON LAND
0
Research Products
16PEACE, JUSTICE AND STRONG INSTITUTIONS
1
Research Products
17PARTNERSHIPS FOR THE GOALS
1
Research Products
Documents
90
Citations
972
h-index
16
Documents
99
Citations
600
Scholarly Output
7
Articles
4
Views / Downloads
21/31
Supervised MSc Theses
0
Supervised PhD Theses
0
WoS Citation Count
7
Scopus Citation Count
7
Patents
0
Projects
0
WoS Citations per Publication
1.00
Scopus Citations per Publication
1.00
Open Access Source
7
Supervised Theses
0
| Journal | Count |
|---|---|
| Thoracic Research and Practice | 4 |
| Balkan Medical Journal | 1 |
| Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi | 1 |
Current Page: 1 / 1
Scopus Quartile Distribution
Competency Cloud
7 results
Scholarly Output Search Results
Now showing 1 - 7 of 7
Letter The Necessity of Bronchiectasis Registries - The Turkish Registry of Bronchiectasis(Galenos Publ House, 2026-01-20) Kizilirmak, Deniz; Martinez-Garcia, Miguel Angel; Cicek, Sedat; Coskun, Aysin Sakar; Kilinc, Oguz; Edis, Ebru CakirArticle Turkish Thoracic Society Declaration on Peace and Health the Importance of Breathing in a World Without Ware(Galenos Publ House, 2026-01-30) Cetinkaya, Pelin Duru; Toreyin, Zehra Nur; Ozdemir, Hande Yuce; Yasin, Yesim; Kilinc, Oguz; Yorgancioglu, Arzu; Begic, ErencanWar legitimizes the right to kill for its participants, equating victory with moral justification, however, this perceived legitimacy is largely Constructed on the deaths of civilians and other living beings. Medicine, by its very nature, is grounded in the principles of preserving ife, doing no harm, and adhering to scientific and ethical standards, and is therefore fundamentally opposed to the philosophy of war. Wars lead, directly and indirectly, to desaths, disability, displacement, poverty, and long-term public health disasters. Attacks on health Facilities, restrictions on access to food and water, environmental destruction, and air pollution disproportionately affect vulnerable Dopulations, particularly women and children. The psychological consequences of war often evolve into persistent neuropsychiatric conditions, including post-traumatic stress disorder, depression, and moral injury. Peace is not merely the absence of war, it is a prerequisite for health, environmental sustainability, and social well-being. The concept of positive peace strengthens health indicators hrough well-functioning institutions, equitable resource distribution, and the protection of human rights. Within this framework, health professionals and civil society organizations are critical actors in advocating for peace and in making human rights violations visible The Turkish Thoracic Society regards peace as an indispensable condition for public and respiratory health, affirms its opposition to all wars particularly the ongoing atrocities in Gaza-and reaffirms its commitment to sustained, health-based advocacy for peace,Article Citation - WoS: 7Citation - Scopus: 7Effectiveness of a Program To Raise Awareness About Pneumococcal Vaccination Among Physicians and Patients With Chronic Respiratory Diseases: a Multicenter Cohort Study(AVES, 2024-08-27) Karakurt, Z.; Yalnız, E.; Altın, S.; Oruç, Ö.; Uslu, Ö.; Veske, N.Ş.; Kılınç, O.; Sayıner, Abdullah; Kul, Seval; Şimşek, NurdanOBJECTIVE: There is a need to increase patient and clinician awareness on the effectiveness of pneumococcal vaccination in at-risk groups. The aim of the study was to evaluate the effect of reminders for physicians and patients using the vaccination tracking system created in the hospital information management system (HIMS) on the vaccination rate, and the effect of pneumococcal vaccination on pneumonia-related hospitalization and mortality over a 12-month period. MATERIAL AND METHODS: This prospective observational cohort study was undertaken during a 2-year period in 3 tertiary care cen-ters. Patients were followed up for 12 months following vaccination, and hospital admissions and mortality were recorded via HIMS. During the campaign, HIMS transmitted pneumococcal immunization reminder messages in accordance with guideline recommendations to physicians’ computers and patients’ mobile phones. Educational posters on pneumococcal vaccination were posted in outpatient clinics. Regular seminars on the evidence for pneumococcal vaccination were organized. All patients who were hospitalized during the follow-up period for chronic obstructive pulmonary disease (COPD), asthma, lung cancer, or pneumonia were analyzed in relation to their vaccination history regarding clinical outcomes. RESULTS: A total of 29 530 patients were included in the study. During the study period, the annual vaccination rate increased by 74.4% and reached 4.8% in 3 hospitals (P = .001). The rates were 3.9% in patients older than 65 years without comorbidities and 5.2% in those with COPD and asthma (P = .002). In pneumococcal vaccine recipients, pneumonia-related hospital mortality was lower (relative risk (RR) = 0.19, CI 0.09-0.35, P < .001). CONCLUSION: It is possible to raise the rate of pneumococcal vaccination through awareness campaigns. Individuals with COPD and asthma are more willing to receive pneumococcal vaccination. Among patients hospitalized for pneumonia, prior pneumococcal vaccination is associated with lower mortality. © Author(s).Article Echoes of the Past: Are E-Cigarettes the New "Light" Cigarettes(2026-01-29) Yıldız, E.; Kilinç, O.; Çuhadaroǧlu, Ç.Letter Can E-Cigarettes Be the Source of Lead Toxicity(AVES, 2024-11-07) Yılmaz, Seda; Kılınc, Oguz; Atik, Merve Demirci; Demirci Atik, MerveEditorial Echoes of the Past: Are E-Cigarettes the New Light Cigarettes(Galenos Publ House, 2026) Kilinc, Oguz; Yildiz, Ethem; Cuhadaroglu, CaglarArticle Retrospective Evaluation of Covid-19 Incidence During Smoking Cessation Treatment With Varenicline(2024-03-27) Barış, Elif; Ömeroğlu Şimşek, Gökçen; Arıcı, Mualla Aylin; Gümüştekin, Mukaddes; Tosun, Metiner; Kılınç, Oğuz; Şimşek, GökçenBackground: Cholinergic anti-inflammatory pathway endogenously controls inflammatory processes through activation of the α7-nicotinic acetylcholine receptor (α7nAChR). Varenicline, used in smoking cessation therapy, is a full α7nAChR agonist with anti-inflammatory effects. In this study, the frequency of coronavirus disease (COVID-19) was evaluated in patients using varenicline as a smoking cessation treatment. Methods: In this retrospective cross-sectional study, records of the 111 patients admitted to Smoking Cessation Outpatient Clinic of XXXXX University Faculty of Medicine during the COVID-19 pandemic were evaluated. The development of COVID-19 disease according to the status of the patients being positive for SARS-COV-2 was evaluated comparatively in patients who received varenicline or not. Additionally, the disease symptoms were questioned. Results: SARS-CoV-2 PCR positivity was not detected in any of 38 patients who regularly used varenicline out of 68 patients evaluated. SARS-CoV-2 PCR positivity was detected in 13 (43.3%) of 30 patients who received other treatments or irregularly used varenicline (p<0.001). Conclusions: Patients under smoking cessation treatment did not develop COVID-19 during the period of varenicline use compared to non-users suggesting that the medication may have a protective role in the development of COVID-19 which might be further investigated by clinical trials.
